Randomized Clinical Trial of Inhaled Sedation with Sevoflurane in Critically Ill Patients at Risk of Developing the Acute Respiratory Distress Syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517670-15-00

Acronym

AOI 2019 JABAUDON

Enrollment

Registered

2024-10-10

Start date

2023-07-24

Completion date

Unknown

Last updated

2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients in ICU with risks of Acute Respiratory Distress Syndrome

Brief summary

longitudinal evolution in the PaO2/FiO2 ratio

Detailed description

Progression to ARDS will be assessed according to the Berlin criteria, including chest radiographs, Rate of pneumonia, Ventilator-free days, Organ failure-free days, Mortality, Length of ICU-stay, Physiological measures, ICU-acquired delirium, Biomarker measurements

Interventions

DRUGDIPRIVAN 20 mg/ml

DRUGémulsion injectable en seringue pré-remplie

DRUGHYPNOVEL 1 mg/ml

DRUGsolution injectable

DRUGSEVOFLURANE BAXTER 1 ml/ml

DRUGliquide pour inhalation par vapeur

DRUGDexmedetomidine 100 micrograms/ml concentrate for solution for infusion

DRUGNIMBEX 5 mg/ml

DRUGsolution injectable/pour perfusion

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
longitudinal evolution in the PaO2/FiO2 ratio	—

Secondary

Measure	Time frame
Progression to ARDS will be assessed according to the Berlin criteria, including chest radiographs, Rate of pneumonia, Ventilator-free days, Organ failure-free days, Mortality, Length of ICU-stay, Physiological measures, ICU-acquired delirium, Biomarker measurements	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026